Skip to main content
SpringerLink
Log in

New Immunosuppressive Agents for Maintenance Therapy in Organ Transplantation

Focus on Adverse Effects

  • Review Article
  • Immunology-Based Agents
  • Published:
BioDrugs Aims and scope Submit manuscript

Summary

Traditional cyclosporin-based immunosuppressive protocols are associated with relatively high incidences of early acute rejection and late graft loss due to chronic rejection. In addition, long-term immunosuppression with cyclosporin and corticosteroids has been associated with significant metabolic, infectious, malignant and cosmetic adverse effects. In the last decade, the goals of immunosuppression strategies have included not only short-term survival but also graft acceptance, with a low incidence of early acute rejection and minimal long-term toxicity.

Tacrolimus and mycophenolate mofetil are 2 new immunosuppressive agents that have recently been approved for use. The mechanism of action and toxicity profile of tacrolimus are similar to that of cyclosporin. Tacrolimus reduces early acute rejection and is also effective in salvage of allografts with refractory rejection. A wide spectrum of adverse effects, including nephrotoxic, neurotoxic, gastrointestinal, metabolic and hematological effects, has been reported in association with tacrolimus but, unlike cyclosporin, this agent is not associated with hirsutism or gingival hyperplasia. Mycophenolate mofetil, an antimetabolite, has been effective in reducing early acute rejection and in treatment of refractory rejection when used in combination with cyclosporin instead of azathioprine. Its myelosuppressive and gastrointestinal toxicities are mild and reversible, but it may be associated with an increased risk of infections. Both agents permit early corticosteroid withdrawal.

Other new immunosuppressive agents that act on different stages of the cell cycle but that have not yet been introduced for wide clinical use, including sirolimus (rapamycin), brequinar, mizoribine and gusperimus, are also discussed in this review

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bumgardner GL, Roberts JP. New immunosuppressive agents: advances in liver transplantation. Gastroenterol Clin North Am 1993; 22: 421–49

    PubMed  CAS  Google Scholar 

  2. Jindal RM, Popescu I, Emre S, et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. Transplantation 1994; 57: 1395–8

    PubMed  CAS  Google Scholar 

  3. Salmela K, Kyllonen L, Eklond B, et al. Thirty years of renal transplantation in Helsinki. In: Terasaki PI, Cecka JM, editors. Clinical transplants 1994. Los Angeles: UCLA Tissue Typing Laboratory, 1995: 219–28

    Google Scholar 

  4. Thomson AW, Starzl TE. New immunosuppressive drugs: mechanistic insights and potential therapeutic advances. Immunol Rev 1993; 136: 71–98

    PubMed  CAS  Google Scholar 

  5. Cramer DV, Chapman FA, Makowka L. Prevention of vascularized allograft and xenograft rejection in rodents by brequinar sodium. Transplant Proc 1993; 25 Suppl. 2: 23–8

    PubMed  CAS  Google Scholar 

  6. Kue CJ, Chung J, Florentino DF, et al. Rapamycin selectively inhibits interleukin-2 activation of p-70 S6 kinase. Nature 1992; 358: 70

    Google Scholar 

  7. Thomson AW. The immunosuppressive macrolides FK506 and rapamycin. Immunol Lett 1991; 29: 105–12

    PubMed  CAS  Google Scholar 

  8. Brattstrom C, Tyden G, Sawe J, et al. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients [abstract]. Proceedings of the International Congress on New Immunosuppressive Drugs, University of Minnesota, Minneapolis; 1995 Aug 27–30

  9. Johnson EM, Zimmerman J, Duderstadt K, et al. A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients [abstract]. Proceedings of the International Congress on New Immunosuppressive Drugs, University of Minnesota, Minneapolis; 1995 Aug 27–30

  10. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969; 113: 515–24

    PubMed  CAS  Google Scholar 

  11. Platz KP, Sollinger HW, Hullett DA, et al. RS-61443: a new, potent immunosuppressive agent. Transplantation 1991; 51: 27–31

    PubMed  CAS  Google Scholar 

  12. Carr SF, Pap E, Wu JC, et al. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993; 268: 2786–90

    Google Scholar 

  13. Takada K, Asada S, Ichikawa Y, et al. Pharmacokinetics of bredinin in renal transplant patients. Eur J Clin Pharmacol 1983; 24: 457–61

    PubMed  CAS  Google Scholar 

  14. Zaoui P, Serre-Debeauvais F, Bayle F, et al. Clinical use of mizoribine (bredinin) and pharmacologic monitoring assessment in renal transplantation. Transplant Proc 1995; 27: 1064–5

    PubMed  CAS  Google Scholar 

  15. Petrs GJ, Schwartsmann G, Nadal JC, et al. In vivo inhibition of the pyrimidine de-novo enzyme dehydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients. Cancer Res 1990; 50: 4644–9

    Google Scholar 

  16. Dunn JF, Precht A, Hatch J, et al. Brequinar sodium significantly reduces the incidence of steroid-resistant rejection and resource utilization in primary renal transplant patients compared to azathioprine [abstract]. Proceedings of the International Congress on New Immunosuppressive Drugs, University of Minnesota, Minneapolis; 1995 Aug 27–30

  17. Greene S, Watanabe K, Braatz-Trulson J, et al. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995; 50: 861–7

    PubMed  CAS  Google Scholar 

  18. Nishikawa K, Shibasaki C, Takahashi K, et al. Antitumor activity of spergulin: a novel antitumor antibiotic. J Antibiot 1986; 39: 1461–6

    PubMed  CAS  Google Scholar 

  19. Suzuki S. Deoxyspergualin: mode of action and clinical trials. Ann NY Acad Sci 1993; 696: 263–9

    PubMed  CAS  Google Scholar 

  20. Tepper M. Deoxyspergualin: mechanism of action studies of a novel immunosuppressive drug. Ann NY Acad Sci 1993; 696: 123–32

    PubMed  CAS  Google Scholar 

  21. Amemiya H, Japanese Collaborative Transplant Study Group of NKT-01. Immunosuppressive mechanisms and action of deoxyspergualin in experimental and clinical studies. Transplant Proc 1995; 27: 31–2

    PubMed  CAS  Google Scholar 

  22. Kriaa F, Hiesse C, Alard P, et al. Prophylactic use of anti IL-2 receptor monoclonal antibody Lo-Tact-1 in cadaveric renal transplantation: results of a randomized study. Transplant Proc 1993; 25: 817–9

    PubMed  CAS  Google Scholar 

  23. Cooperative Clinical Trials in Transplantation (CCTT) Research Group. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a cooperative pilot study (report 1). Transplant Proc 1995; 27: 863

    Google Scholar 

  24. Friend PJ, Rebello P, Oliveira D, et al. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody. Transplant Proc 1995; 27: 869–70

    PubMed  CAS  Google Scholar 

  25. Hourmant M, Bedrossian J, Druand D, et al. Multicenter comparative study of an anti-LFA-1 adhesion molecule monoclonal antibody and antithymocyte globulin in prophylaxis of acute rejection in kidney transplantation. Transplant Proc 1995; 27: 864

    PubMed  CAS  Google Scholar 

  26. Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial of humanized anti-TAC with standard immunosuppression for the prevention of rejection in renal transplant recipients [abstract]. Proceedings of the American Society of Transplant Physicians; Chicago; May 1995

  27. Wallemacq PE, Reding R. FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. Clin Chem 1993; 39: 2219–28

    PubMed  CAS  Google Scholar 

  28. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281–90

    PubMed  CAS  Google Scholar 

  29. Christians U, Kruse C, Kownatzki R, et al. Measurement of FK-506 by HPLC and isolation and characterization of its metabolites in blood and urine of liver graft recipients. Clin Chem 1992; 38: 2025–32

    PubMed  CAS  Google Scholar 

  30. Hook MA. Tacrolimus, a new immunosuppressant — a review of the literature. Ann Pharmacother 1994; 28: 501–11

    Google Scholar 

  31. Peters DH, Fitton A, Plosker GL, et al. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46: 746–94

    PubMed  CAS  Google Scholar 

  32. US Multicenter FK 506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110–5

    Google Scholar 

  33. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423–8

    Google Scholar 

  34. Klintmalm GB. FK506: an update. Clin Transpl 1994; 8(2 Pt 2): 207–10

    CAS  Google Scholar 

  35. Jordan ML, Shapiro R, Jensen CWB, et al. FK506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc 1991; 23: 3078–81

    PubMed  CAS  Google Scholar 

  36. Japanese FK 506 Study Group. FK 506: long-term study in kidney transplantation. Transplant Proc 1995; 27: 818

    Google Scholar 

  37. Armitage JM, Kornos RL, Fung JJ, et al. The clinical trial of FK506 as a primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 1991; 23: 3054–7

    PubMed  CAS  Google Scholar 

  38. Griffith BP, Bando K, Hardesty RL, et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation 1994; 57: 848

    PubMed  CAS  Google Scholar 

  39. Schleibner S, Krauss M, Wagner K, et al. FK506 versus cyclosporin in the prevention of renal allograft rejection — European pilot study: six-week results. Transpl Int 1995; 2: 86–90

    Google Scholar 

  40. Todo S, Tzakis A, Reyes J, et al. Intestinal transplantation: 4-year experience. Transplant Proc 1995: 27: 1355

    PubMed  CAS  Google Scholar 

  41. Parsons WH, Sigal NH, Wyvratt MJ. FK506 — a novel immunosuppressant. Ann NY Acad Sci 1993; 685: 22–36

    PubMed  CAS  Google Scholar 

  42. Yamada K, Sugisaki Y, Suzuki S, et al. New morphological changes induced by FK506 in a short period in the rat kidney and the effect of Superoxide dismutase and OKY-046 on them: the relationship of FK506 nephrotoxicity to lipid peroxidation and change in production of thromboxane A2 in the kidney. Transpl Int 1992; 5 Suppl. 1: S564–S7

    PubMed  Google Scholar 

  43. Japanese FK 506 Study Group. Morphological characteristics of renal allografts showing renal dysfunction under FK 506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK 506 nephropathy? Transplant Proc 1993; 25: 624–7

    Google Scholar 

  44. Poryako MK, Gonwa TA, Klintmalm GB, et al. Comparing nephrotoxicity of FK506 and cyclosporine regimens after liver transplantation: preliminary results from the US Multicenter Liver Study Group. Transplant Proc 1995; 27: 1114–6

    Google Scholar 

  45. Bismuth H, European FK506 Multicenter Liver Study Group. Comparison of FK506- and cyclosporine-based immunosuppression: FK506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. Transplant Proc 1995; 27: 45–9

    PubMed  CAS  Google Scholar 

  46. Ochiai T, Ishibashi M, Fukao K, et al. Japanese multicenter studies of FK 506 in renal transplantation. Transplant Proc 1995; 27: 50–3

    PubMed  CAS  Google Scholar 

  47. Neuhaus P, Blumhardt G, Bechstein WO, et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation: a single-center experience. Transplantation 1995; 59: 31–40

    PubMed  CAS  Google Scholar 

  48. Mor E, Patel T, Glabman S, et al. Comparison of short and long-term renal function in liver transplant patients receiving cyclosporin or FK 506. Transpl Int 1994; 7 Suppl. 1: S77–S80

    PubMed  Google Scholar 

  49. Neuhaus P, McMaster P, Calne R, et al. Oral tacrolimus (FK506) therapy in the immediate postoperative period eliminates the need for intravenous administration following liver transplantation [abstract]. Liver Transplant Surg 1995; 1: 432

    Google Scholar 

  50. Nakazato P, Cox K, Concepcion W, et al. Early experience with induction immunosuppression — suggestions for using oral FK 506. Transplant Proc 1991; 23: 3019–20

    PubMed  CAS  Google Scholar 

  51. Busque S, Esquivel CO, Concepcion W, et al. Experience with low-dose oral tacrolimus (FK506) induction therapy in adult liver transplantation [abstract]. Liver Transplant Surg 1995; 1: 432

    Google Scholar 

  52. Guy S, Mor E, Fisher A, et al. Immunosuppression conversion for relief of side effects. Transplant Proc 1994; 26: 3235–6

    PubMed  CAS  Google Scholar 

  53. Busuttil RW, US Multicenter FK506 Liver Study Group. A twoyear follow-up of liver transplantation patients from the US multicenter trial comparing FK506 and cyclosporine [abstract]. Liver Transplant Surg 1995; 1: 432

    Google Scholar 

  54. Reyes J, Jain A, Todo S, et al. Pediatric primary orthotopic liver transplantation under tacrolimus [abstract]. Liver Transplant Surg 1995; 1: 432

    Google Scholar 

  55. Pham SM, Kormos RL, Kawai A, et al. FK506 in clinical cardiac transplantation: a five-year experience [abstract]. Proceedings of the International Congress on New Immunosuppressive Drugs, University of Minnesota, Minneapolis; 1995 Aug 27–30

  56. Sheiner, Mor E, Chodoff L, et al. Acute renal failure associated with the use of ibuprofen in two liver transplant recipients of FK506. Transplantation 1994; 57: 1132–3

    PubMed  CAS  Google Scholar 

  57. Tolkoff-Rubin NE. Dialysis and transplantation. In: Rubenstein E, Federman D, editors. Scientific American medicine. New York: Scientific American Inc., 1996

    Google Scholar 

  58. Sakamoto K, Yamada K, Arita S, et al. Sodium-losing nephropathy and distal tubular damage of transplant kidneys with FK506 administration. Transplant Proc 1995; 27: 826

    PubMed  CAS  Google Scholar 

  59. Jain AB, Fung JJ, Todo S, et al. One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. Transplant Proc 1995; 27: 1099–104

    PubMed  CAS  Google Scholar 

  60. Canzanello VJ, Taler SJ, Wilson DJ, et al. Effects of cyclosporine and FK506 on blood pressure and renal sodium handling after orthotopic liver transplantation. J Am Soc Nephrol 1995; 5: 1910–7

    PubMed  CAS  Google Scholar 

  61. Schleibner S, Krauss M, Wagner K, et al. FK506 versus cyclosporine in the prevention of renal allograft rejection — European pilot study: six week results. Transpl Int 1995; 8: 86–90

    PubMed  CAS  Google Scholar 

  62. Fung JJ, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK506. Transplant Proc 1991; 23: 3105–8

    PubMed  CAS  Google Scholar 

  63. Bronster DJ, Yonover P, Stein J, et al. Demyelinating sensorimotor polyneuropathy after administration of FK506. Transplantation 1995; 59: 1066–7

    PubMed  CAS  Google Scholar 

  64. Mor E, Sheiner PA, Schwartz ME, et al. Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. Transplantation 1994; 58: 380–2

    PubMed  CAS  Google Scholar 

  65. Tamura K, Fujimura T, Tsutsumi T, et al. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic B cell when FK BP-12 content is relatively high. Transplant Proc 1995; 27: 357–61

    PubMed  CAS  Google Scholar 

  66. Dmitrewski J, Krentz A, Mayer AD, et al. FK506 and glucose metabolism: a prospective study in liver transplant recipients [abstract]. Proceedings of American Society of Transplant Physicians; Chicago; May 1995

  67. Steinmuller TM, Klaus-Jurgen G, Schleicher J, et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism — a randomized trial. Transplantation 1994; 558: 669–74

    Google Scholar 

  68. Senninger N, Golling M, Datsis K, et al. Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506. Transplant Proc 1995; 27: 1127–8

    PubMed  CAS  Google Scholar 

  69. Jindal R. Posttransplant diabetes mellitus — a review. Transplantation 1994; 58: 1289–98

    PubMed  CAS  Google Scholar 

  70. Abouljoud MS, Levy MF, Klintmalm GB, et al. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine US multicenter trial. Transplant Proc 1995; 27: 1121–3

    PubMed  CAS  Google Scholar 

  71. Mor E, Facklam D, Hasse J, for the US Multicenter FK506 Study Group. Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 multicenter study. Transplant Proc 1995; 27: 1126

    PubMed  CAS  Google Scholar 

  72. Vathsala A, Weinberg R, Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989; 48: 37–43

    PubMed  CAS  Google Scholar 

  73. Padbury RTA, Gunson BK, Dousset B, et al. Steroid withdrawal from long-term immunosuppression in liver allograft recipients. Transplantation 1993; 55: 789–94

    PubMed  CAS  Google Scholar 

  74. Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 53–6

    PubMed  CAS  Google Scholar 

  75. de Groen P. Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin Proc 1988; 63: 1012–21

    PubMed  Google Scholar 

  76. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorders in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524–9

    PubMed  CAS  Google Scholar 

  77. Sokal EM, Caragiozoglou T, Lamy M, et al. Epstein-Barr virus serology and Epstein-Barr virus associated lymphoproliferative disorders in pediatric liver transplant recipients. Transplantation 1993; 56: 1398

    Google Scholar 

  78. Reding R, Wallemacq P, Firdaous I, et al. FK506 (tacrolimus) in pediatric liver transplantation (OLT): a clinical and pharmacokinetic, bicentric study in 20 recipients [abstract]. Third Joint Congress on Liver Transplantation; London; 1995 Sep

  79. McDiarmid S, Barnes C, Vargas J, et al. Experience with FK506 as primary immunosuppressive therapy after pediatric liver transplantation [abstract]. Third Joint Congress on Liver Transplantation; London; 1995 Sep

  80. Andrews W, Sommerauer JF, Hudgins P, et al. Cumulative immunosuppression and the development of lymphoproliferative disorders following liver transplantation in children [abstract]. Proceedings of American Society of Transplant Physicians; Chicago; May 1995

  81. Hadley S, Samore MH, Lewis WD, et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59: 851–9

    PubMed  CAS  Google Scholar 

  82. Lam KC, Lai LL, Ng RP, et al. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med 1981; 307: 380–6

    Google Scholar 

  83. Wong PYN, Marinos G, Peakman M, et al. FK506 in liver transplantation for chronic hepatitis B: in vitro studies on lymphocyte activation and viral replication. Liver Transplant Surg 1995; 1: 362–70

    CAS  Google Scholar 

  84. Dunn SP, Falkenstein K, Lawrence JP, et al. Monotherapy with cyclosporine for chronic immunosuppression in pediatric liver recipients. Transplantation 1994; 57: 544–7

    PubMed  CAS  Google Scholar 

  85. Fisher A, Schwartz M, Mor E, et al. Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. Transplant Proc 1994; 26: 3106–7

    PubMed  CAS  Google Scholar 

  86. Atikson P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in pediatric transplant patients. Lancet 1994; 345: 894–6

    Google Scholar 

  87. Abu-Elmagd K, Bronsther O, Kobayashi M, et al. Acute hemolytic anemia in liver and bone marrow transplant patients under FK506 therapy. Transplant Proc 1991; 23: 3190–2

    PubMed  CAS  Google Scholar 

  88. McCauley J, Bronsther O, Fung JJ, et al. Treatment of cyclosporine-induced hemolytic uremic syndrome with FK506. Lancet 1989; II: 1516

    Google Scholar 

  89. Kaufman DB, Kaplan B, Kanwar YS, et al. The successful use of tacrolimus (FK506) in a pancreas/kidney recipient with recurrent cyclosporine-associated hemolytic-uremic syndrome. Transplantation 1995; 59: 1737–9

    PubMed  CAS  Google Scholar 

  90. Scarola JA, Maida B, Zimmerman J. Clinical trials [abstract]. Proceedings of the International Congress on New Immunosuppressive Drugs, University of Minnesota, Minneapolis; 1995 Aug 27–30

  91. Kahan BD. Sirolimus: a new agent for clinical renal transplantation. Transplant Proc 1997; 29: 36–8

    Google Scholar 

  92. Murgia MG, Jordan S, Kahan BD. Sirolimus affects neither allograft function nor hypertension in quiescent renal transplant patients [abstract]. Proceedings of American Society of Transplant Physicians; Chicago; May 1995

  93. Lee WA, Gu L, Miksztal AR, et al. Bioavailability improvement of mycophenolic acid through amino acid derivation. Pharm Res 1990; 7: 161–6

    PubMed  CAS  Google Scholar 

  94. Sollinger HW, Deierhoi MH, Beizer FO, et al. RS-61443 (mycofenolate mofetil): a multicenter study for refractory kidney transplant rejection. Ann Surg 1992; 216: 513–9

    PubMed  CAS  Google Scholar 

  95. Klintmalm GB, Ascher NL, Busuttil RW, et al. RS-61443 for treatment-resistant human liver rejection. Transplant Proc 1993; 25: 697

    PubMed  CAS  Google Scholar 

  96. Ensley RD, Bristow MR, Olsen SN, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993; 56: 75–82

    PubMed  CAS  Google Scholar 

  97. Sollinger HW, U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225–32

    PubMed  CAS  Google Scholar 

  98. Hayry P, International Mycophenolate Mofetil Renal Transplantation Study Group. Mycophenolate mofetil (MMF) for acute rejection of cadaver renal transplants: results of a randomized, double-blind, multicenter study [abstract]. Proceedings of American Society of Transplant Physicians; Chicago; May 1995

  99. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded randomised clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029–37

    Google Scholar 

  100. McDiarmid SV. Mycophenolate mofetil in liver transplantation [abstract]. Proceedings of the International Congress on New Immunosuppressive Drugs, University of Minnesota, Minneapolis; 1995 Aug 27–30

  101. Freise CE, Hebert M, Osorio RW, et al. Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation. Transplant Proc 1993; 25: 1758–9

    PubMed  CAS  Google Scholar 

  102. Morris RE, Wang J, Blum JR, et al. Immunosuppressive effects of the morpholinoethyl ester of mycofenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc 1991; 23: 19–25

    PubMed  Google Scholar 

  103. Steele DM, Hullett DA, Bechstein WO, et al. Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant Proc 1993; 25: 754–5

    PubMed  CAS  Google Scholar 

  104. Epinette WW, Parker CM, Jones EL, et al. Mycophenolic acid for psoriasis: a review of pharmacology, long-term efficacy and safety. J Am Acad Dermatol 1987; 17: 962–71

    PubMed  CAS  Google Scholar 

  105. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136: 5–25

    PubMed  CAS  Google Scholar 

  106. Hrelia P, Murelli L, Scotti M, et al. Organospecific activation of azathioprine in mice: role of liver metabolism in mutation induction. Carcinogenesis 1988; 9: 1011–5

    PubMed  CAS  Google Scholar 

  107. Lee HA, Slapak M, Venkat Raman G, et al. Mizoribine as an alternative to azathioprine in triple therapy immunosuppressant regimens in cadaveric renal transplantation: two successive studies. Transplant Proc 1995; 27: 1050–1

    PubMed  CAS  Google Scholar 

  108. Makowka L, Chapman F, Cramer DV. Historical development of brequinar sodium as a new immunosuppressive drug for transplantation. Transplant Proc 1993; 25: 2–7

    PubMed  CAS  Google Scholar 

  109. Makowka L, Sher L, Cramer DV. The development of brequinar sodium as an immunosuppressive drug for transplantation. Immunol Rev 1993; 136: 51–70

    PubMed  CAS  Google Scholar 

  110. Schwartzmann G, Dodion P, Vermorken JB, et al. Phase I study with brequinar sodium (NSC 368390) in patients with solid malignancies. Cancer Chemother Pharmacol 1990; 25: 345–51

    Google Scholar 

  111. Urba S, Doroshow J, Cripps C, et al. Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck. Cancer Chemother Pharmacol 1992; 31: 167–9

    PubMed  CAS  Google Scholar 

  112. Takeuchi T, Iinuma H, Kunimoto S, et al. A new antitumor antibiotic, spergualin: isolation and antitumor activity. J Antibiot 1981; 34: 1619–21

    PubMed  CAS  Google Scholar 

  113. Suzuki S, Amemiya H. 15-Deoxyspergualin — a novel immunosuppressant: experimental studies and clinical trials. Transplant Immunol Lett 1990; 7: 17–9

    Google Scholar 

  114. Amemiya H, Japan Collaborative Transplant Study of Deoxyspergualin. Deoxyspergualin: clinical trials in renal graft rejection. Ann NY Acad Sci 1993; 696: 196–201

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Transplantation, Rabin Medical Center, Petah-Tikva, Israel

    Eytan Mor & Alexander Yussim

  2. Department of Pharmacy, Mount Sinai Medical Center, New York, NY, USA

    Lawrence Chodoff

  3. Department of Surgery, Mount Sinai Medical Center, New York, NY, USA

    Myron E. Schwartz

Authors
  1. Eytan Mor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Yussim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence Chodoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Myron E. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mor, E., Yussim, A., Chodoff, L. et al. New Immunosuppressive Agents for Maintenance Therapy in Organ Transplantation. BioDrugs 8, 469–488 (1997). https://doi.org/10.2165/00063030-199708060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199708060-00007

Keywords

Search

Navigation